Cited by 373Gastrointestinal motility and disordersPelvic floor disorders treatmentsCongenital gastrointestinal and neural anomalies

The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.

Two Randomized Trials of Linaclotide for Chronic Constipation

Open access

Lembo, Anthony J., Schneier, Harvey A., Shiff, Steven J., Kurtz, Caroline B., MacDougall, James E., Jia, Xinwei D., Shao, James Z., Lavins, Bernard J., Currie, Mark G., Fitch, Donald A., Jeglinski, Brenda I., Eng, Paul, Fox, Susan M., Johnston, Jeffrey M.·2011·New England Journal of Medicine

DOI 10.1056/nejmoa1010863

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: Linaclotide is a minimally absorbed peptide agonist of the guanylate cyclase C receptor. In two trials, we aimed to determine the efficacy and safety of linaclotide in patients with chronic constipation. METHODS: We conducted two randomized, 12-week, multicenter, double-blind, parallel-group, placebo-controlled, dual-dose trials (Trials 303 and 01) involving 1276 patients with chronic constipation. Patients received either placebo or linaclotide, 145 μg or 290 μg, once daily for 12 weeks. The primary efficacy end point was three or more complete spontaneous bowel movements (CSBMs) per week and an increase of one or more CSBMs from baseline during at least 9 of the 12 weeks. Adverse events were also monitored. RESULTS: For Trials 303 and 01, respectively, the primary end point was reached by 21.2% and 16.0% of the patients who received 145 μg of linaclotide and by 19.4% and 21.3% of the patients who received 290 μg of linaclotide, as compared with 3.3% and 6.0% of those who received placebo (P<0.01 for all comparisons of linaclotide with placebo). Improvements in all secondary end points were significantly greater in both linaclotide groups than in the placebo groups. The incidence of adverse events was similar among all study groups, with the exception of diarrhea, which led to discontinuation of treatment in 4.2% of patients in both linaclotide groups. CONCLUSIONS: In these two 12-week trials, linaclotide significantly reduced bowel and abdominal symptoms in patients with chronic constipation. Additional studies are needed to evaluate the potential long-term risks and benefits of linaclotide in chronic constipation. (Funded by Ironwood Pharmaceuticals and Forest Research Institute; ClinicalTrials.gov numbers, NCT00765882 and NCT00730015.).

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejmoa1010863

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Stool form scale as a useful guide to intestinal transit time
Lewis, S. J., & Heaton, K. W. (1997) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365529709011203 · Cited by 3,244
Epidemiology of Constipation in North America: A Systematic Review
Higgins, P., & Johanson, J. (2004) · American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2004.04114.x · Cited by 1,048
Chronic Constipation
Lembo, A., & Camilleri, M. (2003) · New England Journal of Medicine · doi:10.1056/nejmra020995 · Cited by 692
Self-citation
Chronic constipation: a survey of the patient perspective
JOHANSON, J. F., & KRALSTEIN, J. (2007) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2006.03238.x · Cited by 617
Development and validation of the Patient Assessment of Constipation Quality of Life questionnaire
Marquis, P., de la Loge, C., Dubois, D., Mcdermott, A., & Chassany, O. (2005) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365520510012208 · Cited by 586
Heat-stable enterotoxin of Escherichia coli: in vitro effects on guanylate cyclase activity, cyclic GMP concentration, and ion transport in small intestine.
Field, M., Graf, L. H., Laird, W., & Smith, P. L. (1978) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.75.6.2800 · Cited by 561
AGA Medical Position Statement on the Diagnosis and Management of Colorectal Neoplasia in Inflammatory Bowel Disease
Farraye, F. A., Odze, R. D., Eaden, J., & Itzkowitz, S. H. (2010) · Gastroenterology · doi:10.1053/j.gastro.2009.12.037 · Cited by 530
An epidemiological survey of constipation in Canada: definitions, rates, demographics, and predictors of health care seeking
Paré, P., Ferrazzi, S., Thompson, W., Irvine, E. J., & Rance, L. (2001) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2001.05259.x · Cited by 445
The burden of constipation on quality of life: results of a multinational survey
Wald, A. M., Scarpignato, C., Kamm, M. A., Mueller‐Lissner, S., HELFRICH, I., Schuijt, C., Bubeck, J., Limoni, C., & Petrini, O. (2007) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2007.03376.x · Cited by 374
Systematic Review on the Management of Chronic Constipation in North America
Brandt, L. J., Prather, C. M., Quigley, E. M. M., Schiller, L. R., Schoenfeld, P., & Talley, N. J. (2005) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2005.50613_2.x · Cited by 344

Show all 18 references

Research works printed but not linked: 1

Martin BC, 2006, Manag Care Interface, 19, 43

Sorted by citations

Bowel Disorders
Lacy, B. E., Mearin, F., Chang, L., Chey, W. D., Lembo, A. J., Simren, M., & Spiller, R. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.02.031 · Cited by 2,866
Self-citation
Gastrointestinal Dysfunction in Parkinson’s Disease
Fasano, A., Visanji, N. P., Liu, L. W. C., Lang, A. E., & Pfeiffer, R. F. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)00007-1 · Cited by 1,016
Emerging Frontiers in Drug Delivery
Tibbitt, M. W., Dahlman, J. E., & Langer, R. (2016) · Journal of the American Chemical Society · doi:10.1021/jacs.5b09974 · Cited by 1,009
American Gastroenterological Association Technical Review on Constipation
Bharucha, A. E., Pembérton, J. H., & Locke, G. R. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.10.028 · Cited by 924
Mechanisms, evaluation, and management of chronic constipation
Bharucha, A. E., & Lacy, B. E. (2020) · Gastroenterology · doi:10.1053/j.gastro.2019.12.034 · Cited by 655
American College of Gastroenterology Monograph on the Management of Irritable Bowel Syndrome and Chronic Idiopathic Constipation
Ford, A. C., Moayyedi, P., Lacy, B. E., Lembo, A. J., Saito, Y. A., Schiller, L. R., Soffer, E., Spiegel, B. M. R., & Quigley, E. M. M. (2014) · The American Journal of Gastroenterology · doi:10.1038/ajg.2014.187 · Cited by 664
Self-citation
Management of functional constipation in children and adults
Vriesman, M. H., Koppen, I. J. N., Camilleri, M., Di Lorenzo, C., & Benninga, M. A. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0222-y · Cited by 457
An approach to the diagnosis and management of Rome IV functional disorders of chronic constipation
Aziz, I., Whitehead, W. E., Palsson, O. S., Törnblom, H., & Simrén, M. (2020) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2020.1708718 · Cited by 413
American Society of Interventional Pain Physicians (ASIPP) Guidelines for Responsible Opioid Prescribing in Chronic Non-Cancer Pain: Part 2 - Guidance
ASIPP, A. (2012) · Pain Physician · doi:10.36076/ppj.2012/15/s67 · Cited by 426
A 12-Week, Randomized, Controlled Trial With a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Linaclotide in Irritable Bowel Syndrome With Constipation
Rao, S. S. C., Lembo, A., Shiff, S., Lavins, B., Currie, M., Jia, X., Shi, K., Macdougall, J. E., Shao, J. Z., Eng, P., et al. (2012) · American Journal of Gastroenterology · doi:10.1038/ajg.2012.255 · Cited by 394
“Likewise, in two large phase 3 trials in patients with chronic constipation, linaclotide signifi cantly improved bowel and abdominal symptoms over 12 weeks ( 17 ).”
BackgroundSelf-citation
Chronic constipation
Camilleri, M., Ford, A. C., Mawe, G. M., Dinning, P. G., Rao, S. S., Chey, W. D., Simrén, M., Lembo, A., Young-Fadok, T. M., & Chang, L. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.95 · Cited by 411
Self-citation
Sex-gender differences in irritable bowel syndrome
Kim, Y. S., & Kim, N. (2018) · Journal of Neurogastroenterology and Motility · doi:10.5056/jnm18082 · Cited by 322
“Eluxadoline 100 mg peroral bid μ- and κ-opioid receptor agonist and δ-opioid receptor antagonist Efficacious in both men and women.(117,118) Contraindicated in patients with history of cholecystectomy.”
Background
Chronic Constipation in the Elderly
Gallegos-Orozco, J. F., Foxx–Orenstein, A. E., Sterler, S. M., & Stoa, J. (2011) · The American Journal of Gastroenterology · doi:10.1038/ajg.2011.349 · Cited by 309
Linaclotide Inhibits Colonic Nociceptors and Relieves Abdominal Pain via Guanylate Cyclase-C and Extracellular Cyclic Guanosine 3′,5′-Monophosphate
Castro, J., Harrington, A. M., Hughes, P. A., Martin, C. M., Ge, P., Shea, C. M., Jin, H., Jacobson, S., Hannig, G., Mann, E., et al. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.08.017 · Cited by 295
Self-citation
Chronic Constipation in the Elderly
Bouras, E. P., & Tangalos, E. G. (2009) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2009.06.001 · Cited by 274
Larazotide Acetate for Persistent Symptoms of Celiac Disease Despite a Gluten-Free Diet: A Randomized Controlled Trial
Leffler, D. A., Kelly, C. P., Green, P. H. R., Fedorak, R. N., DiMarino, A. J., Perrow, W., Rasmussen, H. S., Wang, C., Berčík, P., Bachir, N. M., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.02.008 · Cited by 264
“This level of improvement is similar to what is regarded as clinically meaningful in other conditions with episodic symptoms.(27-29)”
Result
Treatment of autonomic dysfunction in Parkinson disease and other synucleinopathies
Palma, J., & Kaufmann, H. (2018) · Movement Disorders · doi:10.1002/mds.27344 · Cited by 258
“Although it has not been specifically studied in patients with synucleinopathies, randomized, placebo-controlled trials performed in subjects with chronic constipation showed that 290 or 145 lg of linaclotide once-daily 30 minutes before breakfast significantly increased daily spontaneous bowel movements.(174) Potenti…”
Result
Acupuncture for Chronic Severe Functional Constipation
Liu, Z., Yan, S., Wu, J., He, L., Li, N., Dong, G.-R., Fang, J., Fu, W., Fu, L., Sun, J., et al. (2016) · Annals of Internal Medicine · doi:10.7326/m15-3118 · Cited by 247
American Society of Interventional Pain Physicians (ASIPP) guidelines for responsible opioid prescribing in chronic non-cancer pain: Part 2--guidance.
Manchikanti, L., Abdi, S., Atluri, S. L., Balog, C. C., Benyamin, R. M., Boswell, M. V., Brown, K. R., Bruel, B. M., Bryce, D. A., Burks, P. A., et al. (2012) · PubMed · Cited by 243
Chronic idiopathic constipation in adults: epidemiology, pathophysiology, diagnosis and clinical management
Black, C. J., & Ford, A. C. (2018) · The Medical Journal of Australia · doi:10.5694/mja18.00241 · Cited by 231
Familial Diarrhea Syndrome Caused by an Activating GUCY2C Mutation
Fiskerstrand, T., Arshad, N., Haukanes, B. I., Tronstad, R. R., Pham, K. D.-C., Johansson, S., Håvik, B., Tønder, S. L., Levy, S., Brackman, D., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1110132 · Cited by 206
American Gastroenterological Association-American College of Gastroenterology Clinical Practice Guideline: Pharmacological Management of Chronic Idiopathic Constipation
Chang, L., Chey, W. D., Imdad, A., Almario, C. V., Bharucha, A. E., Diem, S., Greer, K. B., Hanson, B., Harris, L. A., Ko, C., et al. (2023) · Gastroenterology · doi:10.1053/j.gastro.2023.03.214 · Cited by 185
Self-citation
Medical Management of Constipation
Portalatin, M., & Winstead, N. S. (2012) · Clinics in Colon and Rectal Surgery · doi:10.1055/s-0032-1301754 · Cited by 172
Safety and efficacy of elobixibat for chronic constipation: results from a randomised, double-blind, placebo-controlled, phase 3 trial and an open-label, single-arm, phase 3 trial
Nakajima, A., Seki, M., Taniguchi, S., Ohta, A., Gillberg, P.-G., Mattsson, J. P., & Camilleri, M. (2018) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(18)30123-7 · Cited by 169
Comparison of efficacy of pharmacological treatments for chronic idiopathic constipation: a systematic review and network meta-analysis
Nelson, A. D., Camilleri, M., Chirapongsathorn, S., Vijayvargiya, P., Valentin, N., Shin, A., Erwin, P. J., Wang, Z., & Murad, M. H. (2016) · Gut · doi:10.1136/gutjnl-2016-311835 · Cited by 162
Constipation
Wald, A. M. (2016) · JAMA · doi:10.1001/jama.2015.16994 · Cited by 144
Pharmacologic Properties, Metabolism, and Disposition of Linaclotide, a Novel Therapeutic Peptide Approved for the Treatment of Irritable Bowel Syndrome with Constipation and Chronic Idiopathic Constipation
Busby, R. W., Kessler, M. M., Bartolini, W. P., Bryant, A. P., Hannig, G., Higgins, C. S., Solinga, R. M., Tobin, J. V., WAKEFIELD, J. D., Kurtz, C. B., et al. (2012) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.112.199430 · Cited by 140
“Linaclotide is a novel, orally administered 14- amino acid peptide approved for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC) (Wensel and Luthin, 2011; Lembo et al., 2011; Chey et al., 2012; Rao et al., 2012).”
BackgroundSelf-citation
New treatments and therapeutic targets for IBS and other functional bowel disorders
Simrén, M., & Tack, J. F. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0034-5 · Cited by 150
Efficacy of drugs in chronic idiopathic constipation: a systematic review and network meta-analysis
Luthra, P., Camilleri, M., Burr, N. E., Quigley, E. M. M., Black, C. J., & Ford, A. C. (2019) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(19)30246-8 · Cited by 143
Clinical Practice Guideline: Irritable bowel syndrome with constipation and functional constipation in the adult
Mearin, F., Ciriza, C., Mínguez, M., Rey, E., Mascort, J. J., Peña, E., Cañones, P., & Júdez, J. (2016) · Revista Española de Enfermedades Digestivas · doi:10.17235/reed.2016.4389/2016 · Cited by 140
Gastrointestinal Dysfunctions in Parkinson’s Disease: Symptoms and Treatments
Poirier, A.-A., Aubé, B., Côté, M., Morin, N., Di Paolo, T., & Soulet, D. (2016) · Parkinson s Disease · doi:10.1155/2016/6762528 · Cited by 130
Management Options for Irritable Bowel Syndrome
Camilleri, M. (2018) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2018.04.032 · Cited by 140
Randomised clinical trials: linaclotide phase 3 studies in IBS ‐C – a prespecified further analysis based on European Medicines Agency‐specified endpoints
Quigley, E. M. M., Tack, J. F., Chey, W. D., Rao, S. S., Fortea, J., Falqués, M., Díaz, C., Shiff, S. J., Currie, M. G., & Johnston, J. M. (2012) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12123 · Cited by 127
“26 These findings are consistent with a previous Phase 2b study of linaclotide in patients with IBS-C(24) and two Phase 3 trials in patients with chronic constipation.(30) As previously reported, there were few SAEs and no deaths in either trial.”
ResultSelf-citation
Constipation‐induced pressor effects as triggers for cardiovascular events
Ishiyama, Y., Hoshide, S., Mizuno, H., & Kario, K. (2019) · Journal of Clinical Hypertension · doi:10.1111/jch.13489 · Cited by 123
Chronic constipation: A critical review
Basilisco, G., & Coletta, M. (2013) · Digestive and Liver Disease · doi:10.1016/j.dld.2013.03.016 · Cited by 122
“A third definition used in clinical trials is a modified version of the Rome criteria in which abnormal bowel frequency (<3 bowel movements/week) is the necessary condition for inclusion [15–19].”
Method
Efficacy and tolerability of guanylate cyclase-C agonists for irritable bowel syndrome with constipation and chronic idiopathic constipation: A systematic review and meta-analysis
Shah, E. D., Kim, H. M., & Schoenfeld, P. (2018) · American Journal of Gastroenterology · doi:10.1038/ajg.2017.495 · Cited by 119
Management of Chronic Abdominal Distension and Bloating
Lacy, B. E., Cangemi, D. J., & Vázquez‐Roque, M. I. (2020) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2020.03.056 · Cited by 132
“Two randomized, double-blind, placebo-controlled studies evaluated the efficacy and safety of linaclotide (145 or 290 mg) in 1276 patients with CIC.(85) Both doses improved symptoms of bloating during the 12-week study (P < .”
BackgroundInfluential
KNOTTIN: the database of inhibitor cystine knot scaffold after 10 years, toward a systematic structure modeling
Postic, G., Gracy, J., Périn, C., Chiche, L., & Gelly, J. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkx1084 · Cited by 116
“com) (3), which is used to treat irritable bowel disease with constipation, and Prialt® (ziconotide, Azur Pharma; www.”
Method
Guanylate cyclase-C as a therapeutic target in gastrointestinal disorders
Waldman, S. A., & Camilleri, M. (2018) · Gut · doi:10.1136/gutjnl-2018-316029 · Cited by 110
“30 In addition, linaclotide improved stool consistency, reduced straining and decreased bloating and abdominal discomfort.”
Background
Randomised controlled trial of mesalazine in IBS
Barbara, G., Cremon, C., Annese, V., Basilisco, G., Bazzoli, F., Bellini, M., Benedetti, A., Benini, L., Bossa, F., Buldrini, P., et al. (2014) · Gut · doi:10.1136/gutjnl-2014-308188 · Cited by 107
Definition, diagnosis and treatment strategies for opioid-induced bowel dysfunction–Recommendations of the Nordic Working Group
Drewes, A., Munkholm, P., Simrén, M., Breivik, H., Kongsgaard, U., Hatlebakk, J., Agréus, L., Friedrichsen, M., & Christrup, L. (2016) · Scandinavian Journal of Pain · doi:10.1016/j.sjpain.2015.12.005 · Cited by 98
“In large clinical trials, linalotide improved abdominal and bowel symptoms in patients with hronic idiopathic constipation [125] and IBS with constipation 126].”
Background
Plecanatide, an Oral Guanylate Cyclase C Agonist Acting Locally in the Gastrointestinal Tract, Is Safe and Well-Tolerated in Single Doses
Shailubhai, K., Comiskey, S., Foss, J. A., Feng, R., Barrow, L., Comer, G. M., & Jacob, G. S. (2013) · Digestive Diseases and Sciences · doi:10.1007/s10620-013-2684-z · Cited by 98
“Thus, the higher incidence of diarrhea observed in clinical evaluations with linaclotide [18] may possibly be due to excessive fluid secretion resulting from uncontrolled activation of GC-C receptors in the GI tract.”
Background
Guidelines for the Diagnosis and Treatment of Chronic Functional Constipation in Korea, 2015 Revised Edition
Shin, J. E., Jung, H., Lee, T. H., Jo, Y., Lee, H., Song, K. H., Hong, S. N., Lim, H. C., Lee, S. J., Chung, S. S., et al. (2016) · Journal of Neurogastroenterology and Motility · doi:10.5056/jnm15185 · Cited by 96
“Linaclotide increased CSBMs in constipated patients, as demonstrated consistently in 2 large RCTs.(167) The most common adverse event was diarrhea and most of the patients experienced the first episode of diarrhea during the initial 2 weeks of therapy.”
BackgroundMethod
Diabetes Mellitus and the Colon
Piper, M. S., & Saad, R. J. (2017) · Current Treatment Options in Gastroenterology · doi:10.1007/s11938-017-0151-1 · Cited by 99
Effects of linaclotide in patients with irritable bowel syndrome with constipation or chronic constipation: a meta-analysis.
Videlock, E., Cheng, V., & Cremonini, F. (2013) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2013.04.032 · Cited by 97
Consensus Review of Best Practice of Transanal Irrigation in Children
Mosiello, G., Marshall, D. C., Rolle, U., Cretolle, C., Santacruz, B. G., Frischer, J. S., & Benninga, M. A. (2016) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/mpg.0000000000001483 · Cited by 93
“Furthermore, new oral drugs such as lubiprostone and linaclotide have been shown effective in adult patients (47,48).”
Background
Management of Constipation in Older Adults.
Mounsey, A., Raleigh, M. F., & Wilson, A. (2015) · PubMed · Cited by 93
Elobixibat and its potential role in chronic idiopathic constipation
Acosta, A., & Camilleri, M. (2014) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x14528269 · Cited by 91
Chronic Constipation, Irritable Bowel Syndrome With Constipation and Constipation With Pain/Discomfort: Similarities and Differences
Rey, E., Balboa, A., & Mearin, F. (2014) · American Journal of Gastroenterology · doi:10.1038/ajg.2014.18 · Cited by 91
Abdominal Bloating: Pathophysiology and Treatment
Seo, A. Y., Kim, N., & Oh, D. H. (2013) · Journal of Neurogastroenterology and Motility · doi:10.5056/jnm.2013.19.4.433 · Cited by 82
“Several multicenter, randomized trials of linaclotide in chronic constipation or IBS-C also demonstrated the beneficial effect in relieving abdominal bloating.(158,159) Thus so far, these 2 novel drugs offer a reasonable therapeutic approach for bloating mainly in IBS-C and functional constipation patients.”
Background
The cGMP system: components and function
Hofmann, F. B. (2019) · Biological Chemistry · doi:10.1515/hsz-2019-0386 · Cited by 88
Effects of a probiotic fermented milk on functional constipation: A randomized, double‐blind, placebo‐controlled study
Mazlyn, M. M., Nagarajah, L. H., Fatimah, A., Norimah, A. K., & Goh, K. (2013) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.12168 · Cited by 87
GUCY2C Opposes Systemic Genotoxic Tumorigenesis by Regulating AKT-Dependent Intestinal Barrier Integrity
Lin, J. E., Snook, A. E., Li, P., Stoecker, B. A., Kim, G. W., Magee, M. S., Garcia, A. V. M., Valentino, M. A., Hyslop, T., Schulz, S., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0031686 · Cited by 84
“This therapeutic potential is underscored by the recent advancement of the oral GUCY2C ligand linaclotide for FDA approval for the treatment of constipation-type irritable bowel syndrome [38].”
Review article: diagnosis, management and patient perspectives of the spectrum of constipation disorders
Sharma, A., Rao, S. S. C., Kearns, K., Orleck, K. D., & Waldman, S. A. (2021) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.16369 · Cited by 84
Linaclotide in Chronic Idiopathic Constipation Patients with Moderate to Severe Abdominal Bloating: A Randomized, Controlled Trial
Lacy, B. E., Schey, R., Shiff, S. J., Lavins, B. J., Fox, S. M., Jia, X. D., Blakesley, R. E., Hao, X., Cronin, J. A., Currie, M. G., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0134349 · Cited by 81
“This 12-week, randomized, double—blind, placebo-controlled clinical trial in CIC patients with moderate to severe abdominal bloating confirms the results observed in the two earlier phase 3 CIC trials of linaclotide, including the significant effect of linaclotide on improving the bowel symptoms of CIC.”
BackgroundMethodResultInfluentialSelf-citation
CFTR Activator Increases Intestinal Fluid Secretion and Normalizes Stool Output in a Mouse Model of Constipation
Çil, O., Phuan, P., Lee, S., Tan, J. A., Haggie, P. M., Levin, M. H., Sun, L., Thiagarajah, J. R., Ma, T., & Verkman, A. S. (2016) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2015.12.010 · Cited by 80
“9).(18) The overall response rate to lubiprostone was approximately 13% in constipation-predominant irritable bowel syndrome patients, of whom approximately 7% responded to placebo.”
Background
The multiple and enigmatic roles of guanylyl cyclase C in intestinal homeostasis
Arshad, N., & Visweswariah, S. S. (2012) · FEBS Letters · doi:10.1016/j.febslet.2012.07.028 · Cited by 76
“Currently, an orally administered synthetic ST mimic, linaclotide [29], has been successfully shown to alleviate constipation [30], and this drug is currently awaiting FDA approval.”
Background
The treatment of gastroparesis, constipation and small intestinal bacterial overgrowth syndrome in patients with Parkinson’s disease
Barboza, J., Okun, M. S., & Moshiree, B. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.1086747 · Cited by 79
“Guanylate Cyclase C Receptor Peptide: Promotes the generation of cyclic guanosine monophosphate that secretes chloride and bicarbonate into the intestinal lumen, increasing luminal fluid secretion and accelerating intestinal transit [38] Linaclotide: 145 -- 290 mcg QD Not evaluated in PD.”
Background
Randomized clinical trial: Efficacy and safety of plecanatide in the treatment of chronic idiopathic constipation
DeMicco, M., Barrow, L., Hickey, B., Shailubhai, K., & Griffin, P. (2017) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x17734697 · Cited by 74
Low-Dose Linaclotide (72 μg) for Chronic Idiopathic Constipation: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial
Schoenfeld, P., Lacy, B. E., Chey, W. D., Lembo, A. J., Kurtz, C. B., Reasner, D. S., Bochenek, W. J., Tripp, K. J., Currie, M. G., Fox, S. M., et al. (2017) · The American Journal of Gastroenterology · doi:10.1038/ajg.2017.230 · Cited by 76
Self-citation
Measuring response in the gastrointestinal tract in systemic sclerosis
Khanna, D., Nagaraja, V., Gladue, H. S., Chey, W. D., Pimentel, M., & Frech, T. (2013) · Current Opinion in Rheumatology · doi:10.1097/01.bor.0000434668.32150.e5 · Cited by 73
“Outcome measures administered at baseline and 12 weeks are: proportion of three or more complete spontaneous bowel movements (CSBMs) per week and an increase of one or more CSBMs from baseline during at least 9 of the 12 weeks [57], and GIT 2.”
Method
Gastrointestinal involvement in systemic sclerosis: An updated review
Nassar, M., Ghernautan, V., Nso, N., Nyabera, A., Castillo, F. J. C., Tu, W., Medina, L., Ciobanu, C., Alfishawy, M., Rizzo, V., et al. (2022) · Medicine · doi:10.1097/md.0000000000031780 · Cited by 73
Effect of linaclotide in irritable bowel syndrome with constipation (IBS‐C): a systematic review and meta‐analysis
Atluri, D., Chandar, A., Bharucha, A., & Falck-Ytter, Y. (2014) · Neurogastroenterology and Motility · doi:10.1111/nmo.12292 · Cited by 71
Senna versus magnesium oxide for the treatment of chronic constipation: A randomized, placebo-controlled trial
Morishita, D., Tomita, T., Mori, S., Kimura, T., Oshima, T., Fukui, H., & Miwa, H. (2021) · American Journal of Gastroenterology · doi:10.14309/ajg.0000000000000942 · Cited by 65
Guanylate cyclase-C receptor activation: unexpected biology
Brierley, S. M. (2012) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2012.10.005 · Cited by 65
“Lembo et al., 2011.”
Medical Management of Constipation in Elderly Patients: Systematic Review
Kang, S. J., Cho, Y. S., Lee, T. H., Kim, S., Ryu, H. S., Kim, J., Park, S., Lee, Y. J., & Shin, J. E. (2021) · Journal of Neurogastroenterology and Motility · doi:10.5056/jnm20210 · Cited by 69
Chronic Constipation: a Review of Current Literature
Sbahi, H., & Cash, B. (2015) · Current Gastroenterology Reports · doi:10.1007/s11894-015-0471-z · Cited by 56
The Paracrine Hormone for the GUCY2C Tumor Suppressor, Guanylin, Is Universally Lost in Colorectal Cancer
Wilson, C., Lin, J. E., Li, P., Snook, A. E., Gong, J., Sato, T., Liu, C., Girondo, M. A., Rui, H., Hyslop, T., et al. (2014) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-14-0440 · Cited by 61
“These translational considerations are underscored by the recent regulatory approval of the oral GUCY2C ligand linaclotide to treat patients with irritable bowel syndrome-constipation type (39), and the initiation of a clinical program to explore its utility in preventing colorectal transformation in humans (ClinicalT…”
Background
Obesity-Induced Colorectal Cancer Is Driven by Caloric Silencing of the Guanylin–GUCY2C Paracrine Signaling Axis
Lin, J. E., Colón‐González, F., Blomain, E. S., Kim, G. W., Aing, A., Stoecker, B. A., Rock, J., Snook, A. E., Zhan, T., Hyslop, T., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-1467-t · Cited by 62
“GUCY2C ligand, received FDA approval for the treatment of constipation-type irritable bowel syndrome (25).”
An Update of Pharmacological Management in Children with Functional Constipation
de Geus, A., Koppen, I. J. N., Flint, R. B., Benninga, M. A., & Tabbers, M. M. (2023) · Pediatric Drugs · doi:10.1007/s40272-023-00563-0 · Cited by 70
“Linaclotide has been proven to be safe and efficient for the treatment of FC and irritable bowel syndrome with constipation in adults [84, 85].”
Background
Agents that act luminally to treat diarrhoea and constipation
Menees, S. B., Saad, R. J., & Chey, W. D. (2012) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2012.162 · Cited by 59
New therapeutic perspectives in irritable bowel syndrome: Targeting low-grade inflammation, immuno-neuroendocrine axis, motility, secretion and beyond
Sinagra, E., Morreale, G. C., Mohammadian, G., Fusco, G., Guarnotta, V., Tomasello, G., Cappello, F., Rossi, F., Amvrosiadis, G., & Raimondo, D. (2017) · World Journal of Gastroenterology · doi:10.3748/wjg.v23.i36.6593 · Cited by 64
Intestinal Cell Proliferation and Senescence Are Regulated by Receptor Guanylyl Cyclase C and p21
Basu, N., Saha, S., Khan, I., Ramachandra, S. G., & Visweswariah, S. S. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.511311 · Cited by 57
“The GC-C agonist linaclotide is currently a drug of choice for the treatment of chronic idiopathic constipation (70).”
Background
Linaclotide: A novel agent for chronic constipation and irritable bowel syndrome
Love, B. L., Johnson, A., & Smith, L. S. (2014) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp130575 · Cited by 58
Randomized Placebo-Controlled Phase 3 Trial of Vibrating Capsule for Chronic Constipation
Rao, S. S. C., Quigley, E. M. M., Chey, W. D., Sharma, A., & Lembo, A. J. (2023) · Gastroenterology · doi:10.1053/j.gastro.2023.02.013 · Cited by 62
Self-citation
Emerging frontiers in drug delivery with special focus on novel techniques for targeted therapies
Yu, L., Liu, S., Jia, S., & Xu, F. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115049 · Cited by 59
Uroguanylin Action in the Brain Reduces Weight Gain in Obese Mice via Different Efferent Autonomic Pathways
Folgueira, C., Beiroa, D., Callon, A., Al–Massadi, O., Barja-Fernández, S., Senra, A., Fernø, J., López, M., Diéguez, C., Casanueva, F. F., et al. (2015) · Diabetes · doi:10.2337/db15-0889 · Cited by 56
“For instance, linaclotide, a synthetic peptide that is structurally related to the endogenous guanylin peptide family, activates GUCY2C and is clinically used for chronic constipation (33).”
Background
The Guanylate Cyclase C—cGMP Signaling Axis Opposes Intestinal Epithelial Injury and Neoplasia
Rappaport, J. A., & Waldman, S. A. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00299 · Cited by 58
Recent advances in understanding and managing chronic constipation
Prichard, D. O., & Bharucha, A. E. (2018) · F1000Research · doi:10.12688/f1000research.15900.1 · Cited by 56
Linaclotide for the treatment of chronic constipation
Bassotti, G., Usai–Satta, P., & Bellini, M. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1494728 · Cited by 55
Chronic constipation: Update on management
Hayat, U., Dugum, M. F., & Garg, S. (2017) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.84a.15141 · Cited by 55
Irritable Bowel Syndrome: Straightening the road from the Rome criteria
Camilleri, M. (2020) · Neurogastroenterology and Motility · doi:10.1111/nmo.13957 · Cited by 39
Pharmacotherapy for Irritable Bowel Syndrome
Camilleri, M., & Ford, A. C. (2017) · Journal of Clinical Medicine · doi:10.3390/jcm6110101 · Cited by 53
“The increase in cGMP may also have effects on sensory afferent neurons, leading to pain inhibition, an effect noted in the phase III clinical trials of the drug that were conducted in chronic idiopathic constipation [86], where abdominal discomfort and bloating improved significantly.”
Background
Bloating and Abdominal Distension: Clinical Approach and Management
Mari, A., Backer, F. A., Mahamid, M., Amara, H., Carter, D., Boltin, D., & Dickman, R. (2019) · Advances in Therapy · doi:10.1007/s12325-019-00924-7 · Cited by 45
Constipation: Evaluation and Management.
Jani, B. S., & Marsicano, E. V. (2018) · Europe PMC (PubMed Central) · Cited by 48
A randomized double-blind placebo-controlled trial on the effect of magnesium oxide in patients with chronic constipation
Mori, S., Tomita, T., Fujimura, K., Asano, H., Ogawa, T., Yamasaki, T., Kondo, T., Kono, T., Tozawa, K., Oshima, T., et al. (2019) · Journal of Neurogastroenterology and Motility · doi:10.5056/jnm18194 · Cited by 47
“In contrast, linaclotide induces defecation by acting on the guanylate cyclase C receptors that exist on the surface of intestinal epithelial cells and raising the concentration of cGMP in the intestinal tract to facilitate the secretion of water into the intestine.(27,28,32,39) cGMP also inhibits the afferent nerves…”
Background
Cystine-knot peptides: emerging tools for cancer imaging and therapy
Ackerman, S. E., Currier, N. V., Bergen, J. M., & Cochran, J. R. (2014) · Expert Review of Proteomics · doi:10.1586/14789450.2014.932251 · Cited by 46
“Although Linaclotide has a macrocyclic structure characteristic of knottins, it is minimally absorbed through the intestinal mucosa [85].”
Background
Function and clinical implications of short‐chain fatty acids in patients with mixed refractory constipation
Shi, Y., Chen, Q., Huang, Y., Ni, L., Liu, J., Jiang, J., & Li, N. (2016) · Colorectal Disease · doi:10.1111/codi.13314 · Cited by 47
Evidence-Based Clinical Guidelines for Chronic Constipation 2023
Ihara, E., Manabe, N., Ohkubo, H., Ogasawara, N., Ogino, H., Kakimoto, K., Kanazawa, M., Kawahara, H., Kusano, C., Kuribayashi, S., et al. (2024) · Digestion · doi:10.1159/000540912 · Cited by 60
Understanding and treating refractory constipation
Bassotti, G., & Blandizzi, C. (2014) · World Journal of Gastrointestinal Pharmacology and Therapeutics · doi:10.4292/wjgpt.v5.i2.77 · Cited by 48
High‐dose linaclotide is effective and safe in patients with chronic constipation: A phase III randomized, double‐blind, placebo‐controlled study with a long‐term open‐label extension study in Japan
Fukudo, S., Miwa, H., Nakajima, A., Kinoshita, Y., Kosako, M., Hayashi, K., Akiho, H., Kuroishi, K., Johnston, J. M., Currie, M. G., et al. (2018) · Neurogastroenterology & Motility · doi:10.1111/nmo.13487 · Cited by 45
Self-citation
Linaclotide: A new drug for the treatment of chronic constipation and irritable bowel syndrome with constipation
Corsetti, M., & Tack, J. F. (2013) · United European Gastroenterology Journal · doi:10.1177/2050640612474446 · Cited by 46
“Hence, a substantial unmet need persists in the treatment of CC.”
MethodInfluential
Safety and efficacy of the sodium-glucose cotransporter 1 inhibitor mizagliflozin for functional constipation: a randomised, placebo-controlled, double-blind phase 2 trial
Fukudo, S., Endo, Y., Hongo, M., Nakajima, A., Abe, T., Kobayashi, H., Nakata, T., Nakajima, T., Sameshima, K., Kaku, K., et al. (2018) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(18)30165-1 · Cited by 50
Functional Constipation: Individualising Assessment and Treatment
Pannemans, J., Masuy, I., & Tack, J. (2020) · Drugs · doi:10.1007/s40265-020-01305-z · Cited by 46
Current and Emerging Treatments for Irritable Bowel Syndrome with Constipation and Chronic Idiopathic Constipation: Focus on Prosecretory Agents
Thomas, R. H., & Luthin, D. (2015) · Pharmacotherapy · doi:10.1002/phar.1594 · Cited by 43
“Current therapeutic options include lifestyle modifications, over-the-counter (OTC) agents, antispasmodics, serotonin agonists, and lubiprostone and linaclotide, two prosecretory prescription drugs approved for the treatment of IBS-C and CIC.”
BackgroundMethodInfluential
Pharmacologic, Pharmacokinetic, and Pharmacogenomic Aspects of Functional Gastrointestinal Disorders
Camilleri, M., Bueno, L. P., Andresen, V., Ponti, F. D., Choi, M., & Lembo, A. J. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.02.029 · Cited by 45
Self-citation
American Gastroenterological Association-American College of Gastroenterology Clinical Practice Guideline: Pharmacological Management of Chronic Idiopathic Constipation
Chang, L., Chey, W. D., Imdad, A., Almario, C. V., Bharucha, A. E., Diem, S. J., Greer, K. B., Hanson, B., Harris, L. A., Ko, C. W., et al. (2023) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000002227 · Cited by 48
“The use of linaclotide might improve the PAC-QOL scores compared with placebo (64); however, data could not be pooled.”
BackgroundSelf-citation
Guanylate cyclase C agonists: emerging gastrointestinal therapies and actions.
Camilleri, M. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.01.003 · Cited by 47
Partially Hydrolyzed Guar Gum Accelerates Colonic Transit Time and Improves Symptoms in Adults with Chronic Constipation
Polymeros, D., Beintaris, I., Gaglia, A., Karamanolis, G., Papanikolaou, I. S., Dimitriadis, G., & Triantafyllou, K. (2014) · Digestive Diseases and Sciences · doi:10.1007/s10620-014-3135-1 · Cited by 42
Chronic constipation and abdominal pain: Independent or closely interrelated symptoms?
Wong, M. Y. W., Hebbard, G., Gibson, P. R., & Burgell, R. (2020) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.14970 · Cited by 46

Authors: Lembo, A. J., Schneier, H. A., Shiff, S. J., Kurtz, C. B., MacDougall, J. E., Jia, X. D., Shao, J. Z., Lavins, B. J., Currie, M. G., Fitch, D. A., Jeglinski, B. I., Eng, P., Fox, S. M., & Johnston, J. M.
Affiliations: Beth Israel Deaconess Medical Center (US)
Forest Laboratories (United States) (US)
Ironwood Pharmaceuticals (United States) (US)
ORCID: Lembo, Anthony J.
Currie, Mark G.
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2011-08-11
Volume: 365
Issue: 6
Pages: 527-536
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa1010863
OpenAlex: W2129385409
Cited by: 373
References: 18
Citations by year: 2026: 16 · 2025: 12 · 2024: 28 · 2023: 22 · 2022: 19 · 2021: 23 · 2020: 23 · 2019: 20 · 2018: 31 · 2017: 24 · 2016: 32 · 2015: 26 · 2014: 26 · 2013: 40 · 2012: 25
FWCI: 31.44
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Funders: Ironwood Pharmaceuticals, Incorporated
Topics: Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
Health Sciences › Medicine › Urology › Pelvic floor disorders treatments
Health Sciences › Medicine › Surgery › Congenital gastrointestinal and neural anomalies
Keywords: linaclotide, chronic constipation, spontaneous bowel movements, diarrhea, drug safety, treatment efficacy
MeSH terms: Adolescent, Adult, Aged, Aged, 80 and over, Chronic Disease, Constipation, Defecation, Diarrhea, Double-Blind Method, Female, Guanylate Cyclase, Humans, Male, Middle Aged, Peptides, Quality of Life, Withholding Treatment, Receptors, Guanylate Cyclase-Coupled, Laxatives, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Two Randomized Trials of Linaclotide for Chronic Constipation

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks